header logo image


Page 650«..1020..649650651652..660670..»

Highly bioactive zeolitic imidazolate framework-8capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke -…

March 18th, 2020 11:46 pm

Rational design of potent antioxidative agent with high biocompatibility is urgently needed to treat ischemic reperfusion-induced ROS-mediated cerebrovascular and neural injury during ischemia strokes. Here, we demonstrate an in situ synthetic strategy of bioactive zeolitic imidazolate framework-8capped ceria nanoparticles (CeO2@ZIF-8 NPs) to achieve enhanced catalytic and antioxidative activities and improved stroke therapeutic efficacy. This nanosystem exhibits prolonged blood circulation time, reduced clearance rate, improved BBB penetration ability, and enhanced brain accumulation, where it effectively inhibits the lipid peroxidation in brain tissues in middle cerebral artery occlusion mice and reduces the oxidative damage and apoptosis of neurons in brain tissue. CeO2@ZIF-8 also suppresses inflammation- and immune responseinduced injury by suppressing the activation of astrocytes and secretion of proinflammatory cytokines, thus achieving satisfactory prevention and treatment in neuroprotective therapy. This study also sheds light on the neuroprotective action mechanisms of ZIF-8capped nanomedicine against reperfusion-induced injury in ischemic stroke.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Read more:
Highly bioactive zeolitic imidazolate framework-8capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke -...

Read More...

NANOBIOTIX 2019 Annual Results – Business Wire

March 18th, 2020 11:46 pm

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext : NANO ISIN: FR0011341205 the Company), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its audited consolidated results for the fiscal year ending December 31, 2019:

2019 was a major year for Nanobiotix. We made significant progress in our clinical development plan and are proud to have received our first market approval in Europe for NBTXR3, under the brand name Hensify, in soft tissue sarcoma of the extremity and trunk wall. R&D expenses reflect the strength of our development plan and some key positions have been hired to sustain the activity. In 2020, we are prioritizing the registration pathway for head and neck cancer in the US and Europe, while also continuing our Immuno-Oncology program and evaluating NBTXR3 in other indications with our partners. Philippe Mauberna, Chief Financial Officer of Nanobiotix

The audited consolidated financial statements for the fiscal year ending December 31, 2019 have been approved by the Companys executive board and reviewed by the supervisory board on March 17, 2020.

Consolidated Income Statement: 1

In K

2019

2018

Total revenue and other income

2,541

3,479

Sales

68

116

Service

40

109

Other sales

28

7

Licenses

-

-

Other revenues

2,473

3,363

Research Tax Credit

2,437

3,251

Subsidies

20

90

Other

17

22

Research & Development (R&D) costs

(30,411)

(20,893)

Selling, General and Administrative (SG&A) costs

(18,909)

(12,653)

Operating loss

(46,779)

(30,067)

Financial loss

(4,133)

(277)

Income tax

(3)

-

Net loss for the period

(50,915)

(30,345)

Financial Review

Total Revenue in 2019 amounted to 2.5M vs. 3.5M in 2018, mainly due to:

Total Operating expenses reached 49.3M in 2019 vs. 33.5M in 2018:

Total consolidated headcount reached 110 as of December 31, 2019 vs. 102 as of December 31, 2018, in line with the Companys growth.

Net loss after tax amounted to 50.9M for the year ending December 31, 2019 (vs. 30.3M loss in 2018).

Cash available as of December 31, 2019 amounted to 35.1M (excluding the amount related to the 2018 research tax credit, which was received in February 2020)

Nanobiotix activities and achievements in 2019

Clinical

First ever radioenhancer to receive European market approval

In April 2019, the Company announced that Hensify received European market approval enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma (STS). Hensify is the brand name for NBTXR3 as approved for the treatment of locally advanced STS.

In July 2019, results from the randomized Phase II/III trial evaluating NBTXR3 in patients with locally advanced STS were published in The Lancet Oncology. The data from the registration study (Act.In.Sarc) demonstrated a significant advantage in both pathological complete response (pCR) and rate of margin-negative resection (R0) for those treated with NBTXR3 activated by radiation therapy (RT) versus RT alone. Data showed that an increase in efficacy was achieved with the addition of NBTXR3, without a significant difference in the safety profile compared to RT alone.

NBTXR3 may present as a valuable option for patients with hepatocellular carcinoma or liver metastasis

During an oral presentation at the ASTRO 2019 annual meeting, Nanobiotix announced phase I results in liver cancer. The study showed promising signs of efficacy for hepatocellular carcinoma (HCC) patients, as every evaluable patient responded and over half (62.5%) reached complete response. Moreover, given that the safety profile was very good, a 5th dose escalation level has been added to the trial.

Clinical collaboration(s)

MD Anderson

In January 2019, the Company announced a clinical collaboration with MD Anderson. This agreement expanded the clinical development plan for NBTXR3, as the nine MD Anderson-led trials will evaluate the product in new indications and patient populations, and should involve around 340 patients.

Pre-clinical collaboration(s)

MD Anderson and Weill Cornell Medical College

At AACR 2019, Nanobiotix presented pre-clinical data from studies currently being conducted through its collaborations with MD Anderson and the Weill Cornell Medical College, demonstrating the efficacy of treatment combinations including NBTXR3, radiotherapy, and anti-PD-1 immunotherapy in treating resistant pre-clinical in vivo lung cancer models.

In November during SITC 2019, Nanobiotix announced new results from an in vivo pre-clinical study showing the generation of adaptive immune response (turning cold tumors into hot tumors), better local control, increased abscopal effect, and significantly increased survival for NBTXR3 activated by RT and anti-PD-1 in combination versus RT alone in combination with anti-PD-1. Additionally, an in vivo RadScopal model showed superior local control along with significant increases in abscopal effect and survival for treatments combining NBTXR3 activated by RT with anti-PD-1 and anti-CTLA-4 versus all other tested combinations.

Financial Events

Registered public offering in the United States

Nanobiotix announced that it planned to conduct a registered public offering of ordinary shares, including in the form of American Depositary Shares (ADSs) in the United States, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission.2

View post:
NANOBIOTIX 2019 Annual Results - Business Wire

Read More...

China reports new progress in drug, therapies against Covid-19 – The Star Online

March 18th, 2020 11:44 pm

BEIJING: China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the Covid-19 (coronavirus) outbreak, according to an official on Tuesday (March 17).

Favipiravir, the influenza drug which was approved for clinical use in Japan in 2014, has shown no obvious adverse reactions in the clinical trial, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference.

More than 80 patients have participated in the clinical trial in The Third People's Hospital of Shenzhen, south China's Guangdong Province, including 35 patients taking Favipiravir and 45 patients on a control group.

Results showed that patients receiving Favipiravir treatment turned negative for the virus in a shorter time compared with patients in the control group.

A multi-centred randomised clinical study led by the Zhongnan Hospital of Wuhan University also suggested that the therapeutic effect of Favipiravir is much better than that of the control group.

Favipiravir has been recommended to medical treatment teams and should be included in the diagnosis and treatment plan for Covid-19 as soon as possible, Zhang said.

A Chinese pharmaceutical company has been approved by the National Medical Products Administration to mass-produce the drug and ensure stable supply, Zhang added.

China is also pushing forward the utilization of some advanced technologies such as stem cell and artificial liver and blood purification in the treatment of severe cases.

Zhang said stem cell therapy proves effective in reducing severe inflammatory reactions caused by Covid-19, as well as reducing lung injury and pulmonary fibrosis in patients.

China has initiated several clinical research programs on stem cell therapy against Covid-19, including a stem cell drug that has been approved for clinical trial and a mesenchymal stem cell therapy.

Stem cell therapy has been used to treat 64 patients in severe and critical condition. Those patients' breathing difficulties were gradually relieved and they were generally cured in eight to 10 days.

The therapy also showed advantages in preventing pulmonary fibrosis and improving the long-term prognosis for patients.

The Chinese Society for Cell Biology and the Chinese Medical Association have jointly issued a guideline to standardize the clinical research and application of stem cell therapy against Covid-19.

Zhang said China is trying to use artificial liver and blood purification technology to treat critically ill patients. Patients receiving this treatment have seen reduced levels of inflammatory factors and improvement in chest imaging.

Their time on ventilator support has been decreased by an average of 7.7 days and the required ICU monitoring time has been shortened. - Xinhua/Asian News Network

View post:
China reports new progress in drug, therapies against Covid-19 - The Star Online

Read More...

Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach – Endpoints News

March 18th, 2020 11:44 pm

The reason why triple-negative breast cancer is such a tough disease to treat is largely given away in its name. Such tumors cant be defined by traditional biomarkers neither estrogen receptors, progesterone receptors, nor excess HER2 protein forcing drug hunters down uncharted new pathways.

Researchers at Vanderbilt-Ingram Cancer Center explored one of them, and turned up with some new suggestions.

In a new paper, the scientists began with the observation that deregulated MYCN a member of the transcription factor family that activates expression of some oncogenes has been implicated in a subset of breast cancers with unfavorable prognostic features and clinical outcomes. They ended by putting forth a new drug regimen that could spark new hope.

Given that patients with TNBC primarily receive systemic cytotoxic chemotherapies that frequently result in unfavorable outcomes, they wrote in Science Translational Medicine, we propose the clinical development of combination BETi and MEKi for patients with advanced TNBC, with parallel evaluation of MYCN as a potential marker for patient selection.

Johanna Schafer, a graduate student working in Jennifer Pietenpols lab, is the first author, while the professor is the senior author.

The MYCN protein, sometimes dubbed N-Myc, has long been studied as a target in neuronal or neuroendocrine tumors, but its role in breast cancer is less clear. Its distinct from MYC (c-Myc), though the two are believed to affect each other.

Their intricate relationship would prove crucial in therapeutic development. But the first question is just how common they are, and according to the study, the two family members are heterogeneously expressed in separate cell nuclei within a given tumor in at least 40% of TNBC tumors. In fact, the expression of MYCN appeared to increase after neoadjuvant chemotherapy, part of the current standard of care.

The prevalence gave them enough reason to think about how to target it. When the team selected a cell line model, they had another finding that MYCN-expressing cells were essentially more prone to resistance to PI3K inhibitors, which block an alternative pathway for tumor growth.

Because the MYC family lack catalytic domains, the team resorted to epigenetic regulators, screening 158 compounds against the cell lines. BET drugs, which block the bromodomain (BRD)-containing family of transcriptional regulators, emerged as the winner.

It echoes an earlier study, done at Michigan State University, showing that the experimental class of molecules can prevent the growth of breast and lung cancers.

But thats not it and heres where the MEK inhibitors come in.

Most of the MYNC-expressing TNBCs also contain MYC-expressing cells, the researchers noted, which can still drive cancer growth. In fact, single-agent treatment with a BETi seemed to have increased MYC expression. Adding trametinib (Mekinist) to the cells, however, decreased the amount of both proteins. The results were further tested and confirmed in mouse models.

As a next step, our research team is proposing the further development and clinical trials of this combination therapy, Pietenpol, the director of Vanderbilt-Ingram and EVP for research at Vanderbilt University Medical Center, said in a statement.

Incyte, which has a pact in place to fund Vanderbilt research such as this study, has a BET inhibitor in early development.

See the original post:
Back to the drawing board for triple-negative breast cancer targets, researchers propose new combo approach - Endpoints News

Read More...

A Second Person Has Been Cured of HIV – Nerdist

March 18th, 2020 11:44 pm

Although most of the news from the world of health and medicine has been quite bleak lately, there are still major strides being made in the sector in an effort to combat the worst illnesses that plague humankind. One such stride was just announced, and its certainly worth celebrating: A second person has been cured of HIV.

In a study published in the medical journal, The Lancet, which comes via Medical News Daily, researchers in London say theyve been able to cure a patient of HIV; meaning the patient tested negative for HIV for an extended period of time (30 months as of March, 2020) despite the lack of antiretroviral therapy.

The person whos been cured, Adam Castillejo, was formerly known only as the London patient in order to protect his identity. But Castillejo, who lives in London, came forward recently, and said that he aims to be an ambassador of hope.

The first person to be cured of HIV, Timothy Ray Brown, an American known originally as the Berlin patient, revealed his identity in 2010, saying that I wanted to do what I could to make [a cure] possible. My first step was releasing my name and image to the public. Brown lived and was treated in Berlin. Incidentally, he is technically the second Berlin patient because the results from treatment of the first one are debatable.

AIDS Policy Project with Timothy Ray Brown (third from left with sunglasses). Griffin Boyce.

Castillejo, as well as Brown, were cured of HIV not by antiretroviral medications, which are often able to drastically mitigate the effects, and transmission rate of, HIV, but rather by stem cell transplants from donor bone marrow. Both Castillejo and Brown hadand may still have, that is unclearcancer along with HIV, and were treated with the stem cell transplants primarily to tackle the former disease. (It seems in Castillejos case doctors and researchers were hoping to cure both simultaneously.)

Both Brown and Castillejo underwent a procedure known as a Hematopoietic stem cell transplantation (or HSCT), which involves injecting bone marrow stem cells from a donor, whos often times a parent or sibling, into the recipients bloodstream. Castillejos HSCT treatment was different from Browns, as well as many others, because it was performed with cells that expressed the CCR5 gene.

A video from the MD Anderson Cancer Center that gives a brief outline of how bone marrow stem cell transplants work.

In Castillejos case, stem cells with genomes that express the CCR5 gene were selected because of the fact that it allows for the production of the CCR5 protein: a protein that makes people far more resistant to HIV-1, which accounts for the vast majority of global HIV infections.

While Castillejo received stem cells that did express the CCR5 gene, Brown did notat least according to the study in The Lancet. In fact, according to a 2017 article in New Scientist (which says that Brown received cells with a mutated CCR5 gene, rather than an unexpressed CCR5 gene), some experts believe the curing of Browns HIV was actually due to a potential side effect of his procedure, known as graft-versus-host disease. According to New Scientist, these experts believe that the donor cells attacked Browns native, HIV-infected immune cells, subsequently killing off the virus.

In Castillejos case, on the other hand, it seems there was no graft-versus-host issue that could account for his diminishment of HIV infection levels beyond whats expected to be detectable. Instead, the authors of the study say that one of the implications here is that the Long-term remission of HIV-1 can be achieved utilizing these kinds of cells. The authors also say this method does not require total body irradiation, which would usually be required in cases like these to weaken a recipients immune system in order to allow them to accept donor cells.

An HIV-infected T cell. NIAID

Unfortunately, it seems the treatment that cured Castillejo of HIV is a nonstarter when it comes to mass deployment. There are fatal side effects associated with HSCT, with host-versus-graft chief among them, and doctors say that it should only be performed when there are no other options left.

Prof. Ravindra Kumar Gupta from the University of Cambridge in the U.K., the lead author of the study, told Medical News Daily that [Its] important to note that this curative treatment is high risk and only used as a last resort for patients with HIV who also have life threatening hematological [blood] malignancies.

But Gupta and the other authors of the study still appear to be optimistic that this stands as a proof-of-concept for the idea of using CCR5 gene editing to cure HIV on a larger scale. They warn in their study, however, that several barriers, including the need for increased gene editing efficiency and a lack of robust safety data, still stand in the way of something that could be used as a scalable strategy for tackling HIV.

What do you think about this method of treating HIV? Do you think gene editing will play a big role in curing HIV, or do you think there are other, more promising treatments worth pursuing instead? Let us know your thoughts in the comments.

Feature image: C. Goldsmith / Eliot Lash

More here:
A Second Person Has Been Cured of HIV - Nerdist

Read More...

Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality – Hematology Advisor

March 18th, 2020 11:44 pm

Patients with splanchnic vein thrombosis (SVT) as a presenting condition of polycythemia vera (PV) or essential thrombocythemia (ET) had a higher risk of death compared with those without SVT at the time of PV or ET diagnosis, according to results of a retrospective study published in Annals of Hematology.

The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including PV, ET, and primary myelofibrosis (PMF), are a group of hematopoietic stem cell disorders that result in an overproduction of red blood cells, white cells, and/or platelets. All 3 of these conditions are characterized by an increased risk of thrombosis, a major cause of morbidity in patients with these diseases.

Rarely,patients with MPN present with thrombosis in splanchnic veins, which supplyblood to the gastrointestinal tract, liver, spleen, and pancreas.

Resultsof previous studies have shown that patients with MPN presenting with SVT aremore likely to be younger and to have disease characterized by specificfeatures, such as a slower rate of disease progression. These findings suggest thatPV and ET in patients presenting with SVT may be a biologically distinct entityassociated with a specific natural history.

In this study, 113 patients with SVT at theinitial presentation of PV or ET were identified in 2 Spanish registries thatincluded 1831 and 1304 patients with PV and ET, respectively, as well as aseparate registry of 926 patients with MPN. The remaining patients with PV orET (n=3587), including those patients who developed SVT following diagnosis ofMPN, comprised the control group. The primary study outcome was survival, withsecondary outcomes including thrombosis,bleeding, disease progression, and second cancer.

Genotypinginformation, available for nearly 90% of cases and controls showed that JAK2 and CALR mutations were detectable in 97% and 2% of cases, and 87% and9% of controls, respectively. In addition MPLmutations were detected in 1.5% of controls.

Themedian ages of patients of the cases and controls were 42 years and 65 years,respectively (P =.0001). Thosepresenting with SVT were significantly more likely to be diagnosed with PVcompared with ET or an unclassified MPN (P<.0001), and to have lower hemoglobin levels (P =.0004), and higher leukocyte (P =.0004), and lower platelet counts (P =.0004) at diagnosis.

This article originally appeared on Oncology Nurse Advisor

Read this article:
Splanchnic Vein Thrombosis at Presentation of Polycythemia Vera or Essential Thrombocythemia Associated With Increased Mortality - Hematology Advisor

Read More...

Coronavirus tests stepped up to stop exodus of frontline NHS staff – HeraldScotland

March 18th, 2020 11:44 pm

Testingfor coronavirus will be ramped up amid criticism that NHS staff are being lost from the frontline over potentially harmless coughs, while private clinics report being inundated by people who can afford to pay for swab checks.

The Scottish Government says some Covid-19 testing on healthcare workers has already started at a local level anda national approach is being developed which will scale up these initial efforts.

It comes amid speculation that a new four-hour test could be made available in Britain.

Scotland reported its third coronavirus death on Wednesdayand First Minister Nicola Sturgeon confirmed schools across Scotland would close by the end of this week as a result of new advice from Government scientists.

They will also close in England, Wales and Northern Ireland.

Ms Sturgeon said many schools had reached a point where they have lost too many staff to continue as normal and would not necessarily reopen after Easter, or even before the summer holidays.

Prime Minister Boris Johnson said schools and nurseries across the UK would be expected to accommodate vulnerable children or the children of critical workers, such as NHS staff and police during the closure, with free school meals continuing to be provided to all eligible youngsters.

He added that exams would not go ahead as planned in May or June, but that pupils would get the qualifications they deserve.

Earlier Mr Johnson told the House of Commons the number of tests that can be carried out each day for coronavirus will be increased from 5,000 to 10,000, with a goal to expand it to 25,000 per day in England within four weeks.

North of the Border, there are three NHS laboratories currently processing tests and the Scottish Government is working with a range of partners to increase capacity to exceed 2,000 tests per day in the coming weeks.

A number of options to expand that further, and as quickly as possible, are being explored.

The Prime Minister said: We are prioritising testing of NHS staff for the obvious reason that we want them to be able to look after everybody else with confidence that theyre not transmitting the disease, and this country is actually far ahead of many other comparable countries in testing huge numbers of people.

It comes as a coronavirus test that reveals who has had Covid-19 but not shown symptoms is close to becoming available in a move being hailed as a game-changer.

The Governments chief scientific adviser, Sir Patrick Vallance, said Public Health Englands (PHE) work on the antibody test is progressing very fast, and will provide valuable insight into the pandemic.

Mr Johnson said: The great thing about having a test to see whether youve had it is suddenly a green light goes on above your head and you can go back to work safe and confident in the knowledge that you are most unlikely to get it again.

So for an economic point of view, from a social point of view, it really could be a game-changer.

You can really see the potential of that advance, which, as I say, is coming down the track.

Sir Patrick added: It is a gamechanger. And the reason its a gamechanger is that it allows you to understand the proportion of the asymptomatic population whos had this disease, but hasnt had symptoms.

Going forward its going to be critically important to be able to monitor this disease well because only by being able to monitor it can we start relaxing measuresagain.

The Scottish Government is increasing community surveillance by enabling 200 GP practices, representing a population of 1.2 million, to test patients for the virus.

Health Secretary Jeane Freeman has also promised to roll out testing to frontline NHS staff so that they do not self-isolate unnecessarily.

However, there has been criticism from medics that the process has been too slow and has left key services understaffed at a time when demand is soaring.

Glasgow GP Margaret McCartney tweeted: Our workload has increased 30-40 per cent in last two days.

I know everyone is very busy but a negative test in a symptomatic person would surely allow us to have a hope of functioning?

British Medical Association Scotland chairman Dr Lewis Morrison said: The impact Covid-19 will have on the NHS could be huge. Frontline workers will be working in very different ways and we will need every pair of hands we can possibly get at this time.

That is why it is essential for NHS staff to be tested for the virus if they suspect they have it.

The Scottish Government has assured us this will happen and we now need to see the details of how staff can access testing as soon as possible, to minimise the number of NHS staff who would otherwise be self-isolating.

Professor Michael Griffin, president of the Royal College of Surgeons Edinburgh, said: The recommendation from the UK Government on Monday that pregnant women should self-isolate, as well as a 14-day isolation of those who have been exposed to family members with symptoms, though understandable, has already put a huge pressure on the NHS workforce.

Thats why its absolutely imperative that healthcare workers are tested for Covid-19 to confirm whether they are infected in order to help prevent the unnecessary exclusion of essential NHS staff at the frontline when the epidemic hits its peak.

A test is available for 375 at the Private Harley Street Clinic in London.

Mark Ali, a doctor at the clinic, said it had been inundated with requests for the test, which can be couriered to and from a client for them to take swabs from their own nose and throat.

Mr Ali said: We are testing lords and ladies, knights, and even doctors and dentists who are worried about catching the disease.

As of March 12, the UK had tested just under 30,000 people more than any other European nation except Italy, which had tested 86,000 and Russia which had tested 80,000.

The US had tested fewer than 14,000 in official Centre for Disease Control (CDC) laboratories, compared to 250,000 in South Korea.

Scotland has carried out 6,091 tests to date. US firm ThermoFisher held talks this week with the Prime Minister, HealthSecretary Matt Hancock, Chief Medical Officer Chris Whitty, Chief Scientific Advisor Sir Patrick Vallance and representatives from Boots, Amazon and pharmaceutical giant Roche.

The firm is believed to have been demonstrating its four-hour testing kit which has been approved for use in the US.

The UK death toll from the virus has reached 104 exceeding 100 for the first time and the number of new cases is accelerating, with 676 new cases confirmed yesterday.

Organisers announced that the Glastonbury music festival and Eurovision Song Contest would not go ahead due to the coronavirus outbreak, with filming also suspended temporarily on BBC soaps including Eastenders and Casualty.

It comes as Chinas top coronavirus expert has warned that herd immunity will not contain the global pandemic because the disease is highly infectious and lethal.

Dr Zhong Nanshan, Chinas senior medical adviser, said: We dont yet have the evidence to prove that if you are infected once, you would be immune for life.

Clinical trials for potential vaccines are under way in China and the US, but is not expected to be ready until at least 2021.

Meanwhile, an antiviral drug used in Japan to treat influenza has shown potential to speed recovery from the novel coronavirus that causes Covid-19. The drug, called called Favipiravir or Avigan, was tested on 340 people in China who had been diagnosed with Covid-19.

Half tested negative for the virus within four days of being given the drug compared to 11 days for the patients not on the antiviral.

Lung conditions were also shown in X-rays to have improved in 91 per cent of participants.

There were also claims in China that patients could be cured using stem cell therapy.

Dr Dongcheng Wu, a doctor and stem cell expert based in Wuhan, the epicentre of the outbreak, said he had successfully treated nine patients who were hospitalised with novel coronavirus pneumonia.

All nine reportedly made a full recovery following stem cell transplants and conventional treatment. Dr Wu said: Yes, it is a cure but it is still very early in the process.

It came as Italy recorded 475 coronavirus deaths in a single day the highest 24-hour spike for any country since the infection emerged in China.

Read more here:
Coronavirus tests stepped up to stop exodus of frontline NHS staff - HeraldScotland

Read More...

Heres how 3D printing could help fight this aggressive type of cancer – TechRadar

March 18th, 2020 11:44 pm

A 3D printer has been used to isolate stem cells from one of the most aggressive types of breast cancer, in a bid to develop a drug which can help in the fight against that particular cancer.

This breakthrough comes from a team of researchers at the University of Girona in Spain, who employed the BCN3D Sigma 3D printer in order to make three-dimensional scaffolds which replicate the structures found in human tissues.

The aforementioned triple negative breast cancer which affects young women is highly aggressive and even after treatment using chemotherapy or radiotherapy, tumor cells still remain in the body.

As a result, one of the most dangerous facets of this cancer is its high relapse rate, and the idea is the 3D scaffolds are used to separate the stem cells which are responsible for causing those relapses so that they can be studied in the laboratory.

And the hope is that could lead to the development of a drug which can exclusively attack those cells, without damaging other parts of the body, therefore avoiding the danger of a relapse after treatment.

Dr Teresa Puig, one of the researchers involved in the project, noted that with triple negative breast cancer, relapses happen with 20% to 30% of patients, and they occur within three to four years.

Before the 3D printing technology became involved, the researchers had been producing cell cultures two-dimensionally, but this technique didnt allow the cells to be effectively separated.

Now that isolation can be achieved, close investigation of the stem cells will hopefully find the bio-indicators responsible for the tumors, and a suitable drug along the aforementioned lines can then be developed.

Read more here:
Heres how 3D printing could help fight this aggressive type of cancer - TechRadar

Read More...

For the second time in the world, an HIV patient is cured – Medical Progress – Medical Progress

March 18th, 2020 11:44 pm

An HIV patient recovered with a stem cell transplant. He became the second patient in the world to recover from this disease.

an HIV patient who received a stem cell transplant is now cured. He has become the second patient in the world to recover from the disease, his doctors announced Tuesday, March 10.

Almost ten years after the first confirmed case of an HIV patient who managed to get rid of it, this second case, known as the London patient, has shown no signs of the virus for 30 months, according to the results published in the journal The Lancet HIV.

In March 2019, Professor Ravindra Gupta, of the University of Cambridge, announced that this man diagnosed with HIV in 2003 was in remission, having shown no sign of the virus for 18 months. The doctor had however called for caution, insisting on the term of remission and not healing, asking for more time.

We suggest that our results represent a cure for HIV

A year later, his team took this step. We suggest that our results represent a cure for HIV, they write, after testing samples of blood, tissue, sperm. We tested a fairly considerable number of places where the virus likes to hide and practically everything was negative, apart from a few fossil remains of non-active virus, Pr Gupta told AFP. It is hard to imagine that all traces of a virus that infects billions of cells have been eliminated, he said.

Like the Berlin patient, the American Timothy Ray Brown considered cured in 2011, this London patient underwent a bone marrow transplant to treat blood cancer, and thus received stem cells from donors carrying a rare genetic mutation that prevents HIV from taking hold, CCR5.

Scientists point out that the procedure used for the two recovered patients is very cumbersome and risky, asking ethical questions, as Professor Gupta points out.

Is the London patient really healed? Asked Sharon Lewin of the University of Melbourne. The data () is of course exciting and encouraging, but in the end, only time will tell, she noted, saying it would take more than a handful of HIV-cured patients to assess the likelihood of a late and unexpected resumption of virus replication .

Almost 38 million people are living with HIV worldwide, but only 62% are receiving triple therapy. Nearly 800,000 people died in 2018 from HIV-related conditions. The emergence of drug-resistant forms of HIV is also a growing concern.

Read the rest here:
For the second time in the world, an HIV patient is cured - Medical Progress - Medical Progress

Read More...

Buckley couple thank community for their support as dad-of-two receives life-saving treatment | The Leader – LeaderLive

March 18th, 2020 1:50 am

A BUCKLEY man is one step closer to a clean bill of health after receiving life-saving treatment.

The Leader previously reported that Matt Davies was given 12-months to live without a stem cell transplant, which sparked a massive support network, with thousands signing up to become a donor.

Wife Sarah Davies urged people to sign up to become a donor, which could save the lives of many people and over 7,000 had signed up from her link alone.

Before Christmas, Matt was given the news that there was a match for him and he could start his treatment in January.

She told the Leader: It was a success, at the moment the cells in his body are 99.5 per cent donor and 0.5 per cent his. In time they will be 100 per cent donor so its definitely working which is fantastic.

We are on day 67 and on day 100 we can have a bone marrow scan to find out what stage we are.

GvHD is our biggest worry at the moment. Small amounts after a transplant can be good because it means his body is fighting but in huge amounts it can be damaging. It is starting to affect his gut now.

Because we live in Wales and have done for several years, we couldnt get the funding for the therapy which is what the Christie does, but we are now in the process of getting the drug for him, we are in constant talks so its a frustrating game at the moment.

We need to start this medication to get rid of this GvHD before it becomes chronic, so we are still in the process of getting that drug but hes doing really well.

Graft versus host disease (GvHD) is a condition that might occur after a transplant. In GvHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells then attack the body.

Matt was diagnosed with cancer last year and beat it, however less than eight months later after having his three-monthly routine bone marrow results he was told the leukaemia was back and his only option was a stem cell transplant.

He has since made significant progress however the pair say they are worried about the latest coronavirus outbreak due to Matt essentially having no immune system.

Sarah said: At the moment with coronavirus its very scary because he has a low immune system, he is basically starting from scratch with his immune system so cant get immunisations until he is one year old. We have decided to take the kids out of school because we dont want him catching anything.

Hes done absolutely fantastic and is now back to eating.

Matt has been really lucky. They are pleased with his progress, but they would like his GvHD levels to be lower.

Although Matt faced no real complications during the treatment however has lost a significant amount of weight.

A JustGiving Page has been set up to raise funds for the Christie in Manchester where Matt has been receiving his treatment.

Sarah added: Even still now I will be walking somewhere and random people who Ive never met before will ask me how he is doing. Its actually been so positive. I dont think people realise how much it has helped, just them asking it has really helped us get through this and knowing that a lot of people are supporting us.

On social media we have spoken to so many people in similar situations as ours, its about helping one another, and we have made friends for life.

Thank you so much for your support, it means a lot to us and its lovely for us to read all the comments, even if we cannot reply to them all.

Matts progress can be found on social media via the Team Davies Facebook and Instagram page.

Read more:
Buckley couple thank community for their support as dad-of-two receives life-saving treatment | The Leader - LeaderLive

Read More...

Many Federal Workers Must Still Go to Work Because Agencies Are Scared to Death of Making Decisions – Law & Crime

March 18th, 2020 1:50 am

Despite dozens of federal employees testing positive for the COVID-19 coronavirus this month, and despite the White House asking executive agencies to offer maximum telework flexibilities to eligible workers, most of the 2.1 million people who make up the federal workforce are reportedly still being forced to report to their offices.

For weeks, the Trump administration said it was preparing federal employees to be capable of handling a heavy workload while telecommuting, but the administration has been very slow in rolling out any specifics regarding the transition and very few on the federal workforce are currently being permitted to work remotely. That includes many who told the Washington Post on Sundaythat they are already fully set up to work from home.

One senior manager at a federal agency who spoke on the condition of anonymity told the Post that those in charge are scared to death to make decisions on remote work without getting explicit approval from the top.

Every agency is scared to death to do anything without getting approval, and they dont want to be first, the senior manager said.

Lauri Dahlem, a legal assistant at the Social Security Administrations disability hearing office in Michigan, told the Post that her request to work remotely was denied despite the fact that her husband was recovering from complications from a stem cell transplant to treat cancer and all of her work can be completed from home.

My supervisor said I was exempted because Im only taking care of someone whos sick, said Dahlem, an Army veteran and former military police officer.I want to work. Im a very capable worker. Its insane.

Dahlem also noted that all eight of the administrative law judges that work in her office were still hearing cases in-person as of Friday.

Were seeing agency after agency not release people to work from home, David Cann, director of field services and education at the American Federation of Government Employees, also told the news outlet.If Im a manager who is a jerk, or disengaged, theyre saying, Im not going to do it.

[image via Drew Angerer/Getty Images]

See the rest here:
Many Federal Workers Must Still Go to Work Because Agencies Are Scared to Death of Making Decisions - Law & Crime

Read More...

Coronavirus: How are countries flattening the curve and do lockdowns work? – Sydney Morning Herald

March 18th, 2020 1:50 am

Normal text sizeLarger text sizeVery large text size

You can't see the virus behind the world's latest pandemic with the naked eye but, plotted on a graph, it looks like one side of a mountain, climbing skyward as case numbers soar past 197,000 people in little more than three months. Eventually, epidemiologists say, that trajectory will start to fall. Immunity in the population will build up against the mystery illness, now known as COVID-19, and it will begin to die out.

But in the middle, there will still be that mountain peak the curve everyone is talking about. The steeper it is, the more exponential the spread of the virus; the flatter it is, the slower, the less stress on health services, and the more lives that will be saved in the months ahead.

So how do we flatten the curve? What is herd immunity? And what are countries around the world, including Australia, doing to fix the picture?

This graph shows the theory behind "flattening the curve". Many doctors including in Australia say the capacity of most healthcare systems fall below the dotted line, making the peak likely to be even more intense and the need for containment, not just a slowdown more critical.Credit:Matthew Absalom-Wong

The fight against COVID-19 is about medicine, of course. But its also about mathematics (and money). When a new epidemic explodes onto the scene, experts look for two main numbers: how many people each patient will infect and how many people will die from the disease. This helps them plot an arc for the outbreak: how far it will likely spread before a vaccine is rolled out or enough people who have recovered from the illness with virus-fighting antibodies in their system build up "herd immunity" against it.

Flattening this curve means slowing how fast the virus moves through the community. There might still be a lot of cases. But limiting opportunities for the bug to jump from person to person by adopting "social distancing" measures (such as staying 1.5 metres away from others and avoiding public spaces) as well as improving hygiene and isolating those infected or exposed will stretch out the spread of COVID-19 over time, giving doctors, economies (and vaccine-makers) space to breathe.

If the curve keeps climbing, we will see a surge of cases needing medical intervention all at once and hospitals will likely run out of life-saving machines such as ventilators, which have been critical in treating patients stricken by more serious cases of the respiratory illness. That would push up the death toll and force impossible triage choices like the ones already facing doctors on the frontlines of the Italian outbreak (where an age limit has even been proposed in intensive care wards to free up beds for a growing number of younger patients in their 40s and 50s). It's why some doctors, including in Australia, say simply flattening the curve will not be enough to push it back into the reach of the healthcare system - the virus must be stopped in its tracks through containment in line with what the World Health Organisation is calling for, and even the lockdowns seen in China.

Loading

So far it's estimated about one in five people infected with the new virus will need medical intervention such as ventilation to recover and about 1 per cent of all patients will die. That's 10 times higher than the mortality rate for seasonal flu but still much less than the first (and now infamous) coronavirus outbreak SARS in 2003. Unfortunately, the new virus is also more infectious. Each person with COVID-19 is likely to infect two or three people meaning that growth curve can quickly become exponential, according to the Grattan Institute.

Every day counts once the pandemic clock starts ticking, warns Dr Michael Ryan, who heads up the WHO's emergency response team. "Be fast. Have no regrets," he told the world on March 13. "You must be the first mover. The virus will always get you if you dont move quickly."

During the world's last severe pandemic, the 1918 Spanish flu, the US city of Philadelphia took 14 days to mount a public health response after its first case, even pressing ahead with a big public march. St Louis, meanwhile, cracked down on people's movement and gatherings within just two days of the influenza strain entering its borders. By the end of the crisis, its death toll was less than half of Philadelphia's.

Dr Stephen Duckett and his colleagues at Grattan have been tracking the scale and speed of new COVID-19 infections in nations all around the world. Cases might appear in just a trickle at first but, once countries crack the 100 mark, the virus seems to either explode rapidly such as in China initially, and then Iran, Italy, the US, and Spain or slow to a flatter line as has been recorded elsewhere including Singapore and Hong Kong. Dr Duckett says nations that moved fast to test and track suspected cases and then brought in tough social distancing or containment measures along the lines of the St Louis model have already seen their infection growth fall, even after rapid early spread.

In lieu of a vaccine, countries from China and Italy to the US and Israel are turning to increasingly medieval methods to stem the tide of the pandemic, closing borders, raising barricades and shutting down much of daily life such as restaurants and workplaces. Other countries like Singapore and Taiwan have brought their case loads under control by getting ahead of the curve early rather than bringing in lockdowns later, ramping up testing, forensically tracing cases back to other people who may have been exposed and making social distancing the norm. (The Philippines has even temporarily quarantined its financial markets, becoming the first country to shut down financial trading in response to the pandemic).

Australia still has comparatively few patients with COVID-19 compared to other parts of the world but our own curve is accelerating. New cases have more than tripled in the past week alone, climbing from 112 on March 10 to 454 as of March 17.

"We're on the scary part of the curve," Dr Duckett says. "Italy had about the same number of cases on February 26, and now has more than 28,000."

In places like Italy, patients doubled roughly every two days. This past week, Australian cases doubled about every 3-4 days, Dr Duckett says, putting us on a similar trajectory to the UK and Spain.

Australian health authorities have also been meeting daily to wargame likely infection rates. Deputy Chief Medical Officer Paul Kelly has said the best outcome is that the virus infects just 20 per cent of the Australian population 5 million people but 60 per cent of Australians, or 15 million, could catch it, a catastrophic scenario for hospitals.

The Morrison government is ramping up medical resources and staff and has already banned "non-essential" indoor gatherings of more than 100 people, (and public events over 500). But so far it's stopped short of telling people to stay home from work, school or restaurants or off public transport in line with some other countries like the US and the UK. As the outbreak gathers steam, many experts, including doctors, are now asking: why wait?

Prime Minister Scott Morrison says Australian schools, like those in Singapore, will stay open at this stage, based on advice closures would cause unnecessary disruption considering only a tiny fraction of confirmed COVID-19 cases so far have been in children. Health Minister Greg Hunt says we need to adopt a "war-time spirit" and work together to get through the next few months. Of course, under the exponential maths of contagion, that actually means our lives need to take a step (or two) farther apart. Chief Medical Officer Brendan Murphy urges people to think before every physical interaction - washing their hands, cutting out handshaking and kissing hello and keeping clear of others as much as possible. (The US, meanwhile, is telling people to avoid meeting in groups of more than 10 and in Austria that number is down to a cosy five.)

COVID-19 first emerged in humans in late 2019, at a wet market in the sprawling city of Wuhan, China. At first, local authorities were perplexed by the mysterious cases of pneumonia and tried to keep them quiet. The illness was not formally linked to a new strain of coronavirus until early January, when millions of people were already travelling for the country's biggest holiday, Lunar New Year. Infections exploded.

Loading

But then China's Communist government did something without precedent in modern times it locked down cities and transport across huge swathes of the country, grounding tens of millions. Factories shut down. Schools and offices closed. Streets emptied.

At the time, such a move seemed unthinkable in a Western democracy (and there are still concerns for those stuck under Wuhan's enduring lockdown). But, in the maths, it appears to be working. China was clocking up more than 3000 new cases a day in early February. By mid-March, that number had fallen to less than 30. Its government has already claimed "a great victory" over the virus, even as it prepares for a possible second wave. The WHO says the turnaround is a sign the pandemic can still be contained with "aggressive measures", lashing countries for their slow responses thus far.

But it's less clear if lockdowns will work for Europe or the Middle East, the next frontiers of the pandemic. In Italy and Iran, early cases appeared to again spread under the radar until a sudden surge hit hospitals (and even Iran's parliament). Both governments were slow to act; in Iran, for reportedly political reasons. In Italy, the government was at first reluctant to impose such draconian measures on its densely populated cities, like turning soccer fans away from matches or closing bars. But blockades in the north, where the outbreak began, failed to stop infections leaking into the rest of the country and beyond.

Now Italy has gone into its own style of lockdown (followed by countries such as Spain, France and Germany, as cases in those nations also rise). People are mostly staying home, shops are running on restricted hours and people queuing for supplies must stand 1.5 metres apart. From their windows, Italians in home quarantine sing to each other.

Some experts point out that the two countries which appear to have turned the tide on a rapid outbreak China and South Korea have gone further than just lockdowns. Knowing most infections so far have come from close contact in hospitals or family groups, those with (and sometimes without symptoms) are taken out of their homes and put into hospital isolation instead a move recommendedby the WHO. Milder cases are kept together in huge pop-up fever clinics, often in converted stadiums and gymnasiums, and those still being tested kept away from confirmed cases, after old horror stories of infection circulating in SARS quarantine.

Loading

Both countries, including success stories such as Singapore, Hong Kong and Taiwan, have also been aggressively hunting for cases temperatures are taken before entering any building. If you have a fever, you must roll up to a specialised clinic or "drive-through" for testing.

These parts of the world have been hit hard by dangerous coroanvirus outbreaks of the past, including SARS, Dr Duckett notes, and so their people were already primed for the health checks to come. When word came from China that another coronavirus had jumped from animals to humans, countries like Singapore and Taiwan acted quickly. Social distancing has since been playing out without need for stricter lockdowns or domestic travel bans. While Hong Kong faced criticism for not closing its borders to mainland China fast enough, months of anti-Beijing protests means schools were already teaching online and many people working from home.

South Korea, meanwhile, saw cases erupt within a religious sect and quickly deployed particularly exhaustive detective work to track down close contacts of known cases famously using CCTV to trace people back to a specific bus or taxi and even prosecuting those who lied about their movements.

The island nation of Singapore looked in danger of being overrun in February when it was recording the second-highest volume of cases outside China. But it has since flattened its own curve through quick detection and diagnosis as well as strictly enforced home quarantines (featuring spot checks and twice-daily location monitoring with serious penalties applying for a breach.) Meanwhile, countries such as China, Iran and Israel are deploying their notoriously invasive surveillance networks, including tracking phones, to keep tabs on people under isolation and close in on suspected cases.

Australia also has powers to order people into quarantine and some states such as Victoria have started to mobilise police forces to help enforce such orders if required. But other experts including Adjunct Professor at UNSW Bill Bowtell, who helped design Australia's response to the AIDS crisis, have warned punitive measures will only keep people away from testing clinics.

Lining up for a "fever clinic" at Sir Charles Gairdner hospital in Perth.Credit:Nine

WHO director general Tedros Adhanom Ghebreyesus has blasted governments around the world for giving up on widespread testing and contact tracing, "the backbone" of any response, even as they ramp up social distancing measures.

"You cannot fight a fire blindfolded and we cannot stop this pandemic if we don't know who is infected," he said on March 16. "Test every suspected case. If they test positive, isolate them and find out who they have been in contact with. And test those people too."

A lab test for samples of the virus was created quickly. But faster blood tests are still only widely available in China, where diagnosis has been industrialised. At a fever clinic, you will be met by a healthcare worker in full protective gear, testing white blood cell counts and deploying handheld portable CAT scanners to check for the tell-tale "ground glass" inflammation of COVID-19 in the lungs. Even there, a recent study found two thirds of reported cases could be traced back to undiagnosed patients suggesting the virus could be spreading under the radar even from people with fewer symptoms who shed less virus.

In the US, low testing rates and diagnosis delays from a botched roll-out of intial tests has been blamed for a sudden explosion of cases across Washington, New York and California many fear the US has since missed its window for containment.

As test kits run low elsewhere, Australia is only testing people considered at risk either from recent overseas travel, exposure to a confirmed case or, in some cases, an unexplained and severe bout of pneumonia. But aged care residents and doctors with symptoms can now be tested too. Health Minister Greg Hunt insists Australia is still testing more than most countries: 81,000 tests so far, with an additional 97,000 kits set to arrive in clinics.

The term "herd immunity" has now also gone viral amid speculation Britain's government was lagging behind other nations in imposing social distancing measures as part of a bold plan to allow the virus to sweep through the population, (and so build up their immunity against it).

In the modern era, community resistance to a virus is commonly achieved through a vaccine. Experts, including in Australia, have warned that stalling protections against COVID-19 for the sake of encouraging natural resistance among "the herd" could be "catastrophic", costing lives without much slow down.

The United Kingdom still plans to seal off those considered particularly vulnerable to complications from the new virus, including the old, unwell and pregnant women, for three months. But it's since brought forward social distancing - following the US in announcing new measures warning people to stay home from work and to avoid crowded public places such as pubs and cinemas.

Now the Netherlands has revealed it will embrace a COVID-19 strategy of its own based on herd immunity, saying mass lockdowns are not feasible.

Analysis of virus-fighting strategies by the Imperial College London found targeted measures such as isolating those exposed to the virus or at risk of serious complications could reduce peak demand on hospitals by about two thirds. But researchers noted this would still result in hundreds of thousands of deaths and instead recommended a wider "suppression" where more people in the community stay home.

The problem, as Professor Murphy in Australia has also stressed, is keeping it up over the months ahead without burn out. "You can't just shut things down for two weeks and that's it. It has to keep going."

Sherryn Groch is the explainer reporter for The Age and The Sydney Morning Herald.

Read the original post:
Coronavirus: How are countries flattening the curve and do lockdowns work? - Sydney Morning Herald

Read More...

Coronavirus Fear- New York Bans All Gatherings that Exceed 500 People – TheHealthMania

March 18th, 2020 1:50 am

Museums in New York have closed their doors to the public, the citys opera is silent, Broadway lights are fading as the city bans all gatherings exceeding 500 people.

NY Governor Andrew Cuomo has already publicized this restriction on gatherings hat include more than 500 people. However, it is just a temporary ban and soon the coronavirus is under control, everything would be back to normal he says.

He has also announced the time for this ban. It would be imposed this Friday, at 5 pm in the evening, all across the US. But it doesnt include public services centers like hospitals, dispensaries, nursing homes, schools, etc.

Ban on the Broadway theaters has already been made effective as of April 12thand confirmed by the Broadway League, which is a local organization of producers and proprietors of these Broadway theatres.

Also read- Can Scientists Cure HIV With Stem Cell Therapy?

Governor Cuomo says; As soon as we can go back to normal well go back to normal. But we are still ascending, we are still on the upward trajectory of this disease.

So far, the city has reported 95 confirmed cases of coronavirus, confirms Cuomo. There are 300+ reported cases all across the US and the maximum number of these cases are being reported from a suburban area of New York City, New Rochelle.

Different cultural groups in the city have acknowledged the ban, showing support in coronavirus prevention plan by the government. Three of the most important public places shutting down for an unannounced time include the Metropolitan Museum of Art in three locations, the Metropolitan Opera and Carnegie Hall.

President of the museum, Daniel Weiss said in his statement that; The Mets priority is to protect and support our staff, volunteers, and visitors,

He didnt give any date for Museum reopening.

On the other side, the opera company has confirmed canceling all the shows and performances till March 31st. In addition to that, Carnegie Hall has also confirmed closing for all types of public gatherings till the end of this month.

Closing of all these places shows that the New York administration is taking extreme measures to save the residents from coronavirus outbreak. On Wednesday, Cuomo announced that New York Citys famous St. Patricks Day Parade is postponed for this year. This is the first time in the last 258 years that New York would not witness its historic parade.

Also read- Coronaviruss Life is Just Three Days, New Test Reveals

The city Mayor Bill de Blasio wrote in this tweet implying that the parade is not completely canceled but it may be announced on another day when the country is over this coronavirus fear.

Although coronavirus doesnt seem that dangerous; it only causes minor health problems such as flu, cough, and sore throat, leading to fever. But the older people and those with compromised immunity are at a high risk of complications that could take their lives.

Fortunately, a majority of coronavirus infected people are under treatment and showing recovery. In fact, China has discharged thousands of patients after a complete recovery.

The World Health Organization explains that people at an early stage of infection can be completely recovered within two weeks. However, the severe cases of coronavirus may take up to six weeks to show any sign of recovery. Additionally, the recovery time is highly dependent upon the age and health status of the patient.

View original post here:
Coronavirus Fear- New York Bans All Gatherings that Exceed 500 People - TheHealthMania

Read More...

What does social distancing really mean? – Massive Science

March 18th, 2020 1:50 am

After the World Health Organization (WHO) declared that thecoronavirus outbreakis officially a pandemic, countries around the world have responded accordingly.Universitiesin Canada and the US are closing, non-essential conferences andsports leaguesare being canceled, and people are being advised to halt all travel plans. Anyone can get infected, and the only way to slow down the outbreak is toreduce the number of people getting infected.

Amidst this fear, the most widespread advice for anyone experiencing symptoms is tosocially distance themselves. But what, exactly, does that mean? How is this different from self-isolation? What if you live with family? What if only one person in a family of four is experiencing symptoms? Why is this even important?

How do I know if I need to socially distance myself? How is that different from self-isolation and strict isolation?

Everyone should besocially distancingthemselves! Essentially, that means deliberately distancing yourself from other individuals to reduce COVID-19 transmission rates.

On the other hand,self-isolationor self-quarantine is when you have been in contact with someone who was diagnosed with the coronavirus, or someone who was exhibiting symptoms. Self-isolation also applies for people who are asymptomatic, but have secondary medical issues (diabetes, heart condition) that may make a coronavirus infection more dangerous for them.

Lastly,isolationis when you have been diagnosed with COVID-19, or if you are exhibiting any flu-like symptoms. At this point, you will receive instructions for isolation from your medical provider.

What does social distancing entail?

If possible,do not leave the house. Try to stay at least six feet away from other people, and avoid coming in direct contact with them. Social distancing can also be done by avoiding crowds and mass gatherings, canceling upcoming events, working from home, moving classes online, and communicating electronically instead of personally visiting people.

What if I live with other people?

Even if no one in the household is exhibiting symptoms, it is best to keep distance for at least two weeks, which would be the viruss incubation period.On the other hand, if you need to self-isolate, try to sleep in separate rooms, and keep6 feet away from each other. Frequently wash your hands, andfrequently keep your surrounding areas clean. If possible, avoid touching your face, especially after being in contact with shared possessions or furniture. Wash all plates and utensils thoroughly with warm soap and water, or use a dishwasher with a drying cycle.

How can I help vulnerable people?

If there are vulnerable and at-risk individuals in your neighborhood, consider getting groceries and other essentials for them, and leave the items at their doorstep. Frequently call or check up on your friends and family, since social distancing can be quite lonely.

Why is social distancing important for everyone, including young and asymptomatic people?

According to data fromSouth Korean authorities, translated byDr. Eric Feigl-Ding, young people between the ages of 20 and 29 are carrying 30% of the disease in South Korea, with the majority beingasymptomatic, meaning they are not experiencing symptoms. This means that while you mayfeelfine, if you are sick you can still infect a large number of people by just being out and about!

Why is social distancing important?

By now you have probably seen a version of the graph that explains why we need to "flatten the curve." Through social distancing and pro-active measures, we can not only delay the "peak" of the outbreak, easing demand for hospital and emergency services, but can also reduce how bad the outbreak could be.

Do you still have questions about social distancing, isolation, or anything else about the coronavirus pandemic?

Ask our community of scientists now!

Follow this link:
What does social distancing really mean? - Massive Science

Read More...

GeneDx Celebrates 20 Year History as Pioneer In Genetic Sequencing and Testing – BioBuzz

March 18th, 2020 1:47 am

GeneDx, a global leader in genomics andpatient testing, is celebrating its remarkable 20th anniversary throughout themonth of March.

The Gaithersburg, Maryland company has played an important role in the history of genetic sequencing and the rise of the BioHealth Capital Region as a global biohealth cluster. GeneDx was the very first company to commercially offer NGS (Next Generation Sequencing) testing in a CLIA (Clinical Laboratory Improvement Amendments) lab and has been at the leading edge of genetic sequencing and testing for two decades. The companys whole exome sequencing program and comprehensive testing capabilities are world-renowned.

In its storied 20 yearhistory, GeneDx has provided genetic testing to patients in over 55 countries.The company is known globally as world-class experts in rare and ultra-rarediseases.

In 2000, GeneDx was founded by former National Institutes of Health (NIH) scientists Dr. Sherri Bale and Dr. John Compton. These two genomics experts and thought leaders started GeneDx to complete an important mission: To provide rare and ultra-rare disease patients and families with diagnostic services that were not commercially available at that time.

Prior to launching GeneDx, Bale spent 16 years at NIH, the last nine as Head of the Genetic Studies Section in the Laboratory of Skin Biology. She has been a pioneer during her storied career, publishing over 140 papers, chapters and books in the field. Her 35-year career includes deep experience in clinical, cytogenetic, and molecular genetics research.

Before partnering with Bale to form GeneDx, Compton was an investigator at the Jackson Laboratory, and for the last nine years as a senior scientist in the Genetics Studies Section at the NIH. Comptons work on the molecular genetics of inherited skin disease and expertise in laboratory methodology is known throughout the world. Compton has remarkable experience in the development and application of molecular biological techniques to answer questions about genetics and epidermal differentiation.

GeneDx, like manysuccessful BHCR life science companies, had a humble start, operating initiallyout of the Technology Development Center incubator. Just six years later,GeneDx was acquired by BioreferenceLabs for approximately $17M.

From there, the companylaunched its first array CGH (Comparative Genomic Hybridization) or aCGH testin 2007. An array CGH is also called microarray analysis, which is a atechnique enabling high-resolution, genome-wide screening of segmental genomiccopy number variations (NIH). By 2008, GeneDx had launched its Cardiology NextGeneration Sequencing Panel and by 2011 the company had commercialized itsneurology testing program. In 2012, GeneDx launched its Whole Exome Sequencing (XomeDx) for which it has become so well known in the genomicfield. A year later its Inherited Cancer Panels hit the market. 2018 saw thecompany achieve a significant milestone when it announced ithad performed clinical Exome Sequencing on more than 100,000 individuals.

Both Bale and Comptonhave since retired and GeneDx is currently led by Chief Medical Officer Dr. Gabriele Richard;Chief Innovation Officer Kyle Retterer, MS;Rhonda Brandon, MS

Chief InformationOfficer; and Dr. Sean Hofherr, FACMG, CLIA Laboratory Director & ChiefScientific Officer.

GeneDx has come a longway from its incubator headquarters over the past two decades. With over 450employees, the company continues to deliver on its mission to provide crucialdiagnostic genetic testing capabilities to patients and families across theglobe.

Happy Anniversary GeneDX. Heres to many more.

Steve has over 20 years experience in copywriting, developing brand messaging and creating marketing strategies across a wide range of industries, including the biopharmaceutical, senior living, commercial real estate, IT and renewable energy sectors, among others. He is currently the Principal/Owner of StoryCore, a Frederick, Maryland-based content creation and execution consultancy focused on telling the unique stories of Maryland organizations.

Read the original post:
GeneDx Celebrates 20 Year History as Pioneer In Genetic Sequencing and Testing - BioBuzz

Read More...

Half of people in the US would sell their genetic data for $95 – New Scientist News

March 18th, 2020 1:47 am

By Jason Arunn Murugesu

Jochen Tack / Alamy

As consumer genetic testing has risen in popularity, awareness of the value of genetic data has lagged behind. A survey of people in the US has found that 50 per cent would hand over their genetic data for $95 (70), on average.

Forrest Briscoe at Pennsylvania State University and his colleagues surveyed more than 2000 people about the use of genetic data, which can be stored in databases for police use, at direct-to-consumer genetic test firms, and for medical research.

I really felt like we needed updated information about how the public views these databases, says Briscoe. They are growing quickly, in number and size, but the information being used to inform design and governance is outdated.

Advertisement

The participants, a representative sample of the US population, watched a 3-minute video detailing both the commercial value of genomic data and genetic privacy issues. This included a statement that consumer genetic testing firm 23andMe sells access to its databaseto pharmaceutical firms for $140 per individuals data.

The participants were then split into five groups and asked whether they would grant access to their genetic data either as a donation or in exchange for money to one of five types of organisation: a non-profit hospital, a pharmaceutical company, a tech firm, a university research lab and a US federal research agency.

While 38 per cent said they wouldnt share their data, 50 per cent said they would if they were paid, and 12 per cent said they would do it for free.

The type of organisation that would use their data didnt affect willingness to share. That was a surprise, says Briscoe. We think this makes the case for a common governance framework for DNA databases, whoever they are owned by.

Those who said they wanted to be paid, expected a median of $130, but said they would accept $95 if they also received a health and ancestry report based on their genetic data. People who said they would give their data away said they would pay an average of $75 for such a report.

These results demonstrate the growing interest in maintaining a degree of control over personal information, says Tim Caulfield at the University of Alberta, Canada. The public has been told for decades that this research is essential and valuable and potentially profitable. They may be thinking, Okay, I believe you. Pay me.

Journal reference: PLoS One, DOI: 10.1371/journal.pone.0229044

More on these topics:

See the article here:
Half of people in the US would sell their genetic data for $95 - New Scientist News

Read More...

Free coronavirus sequencing kits for researchers offered by U-M startup – University of Michigan News

March 18th, 2020 1:47 am

ANN ARBORAs doctors, scientists and governments try to get a grip on COVID-19, the University of Michigan startup Arbor Biosciences is providing free kits to capture the genetic code of virus samples.

Variations in that code reveal how the virus has morphed over timefor instance, enabling it to change from an animal disease to one that can be passed from one human to another.

The information could help shed light on how the genes of the virus, SARS-CoV-2, cause the symptoms of the disease COVID-19. But more important in the long run, it could help reveal the factors that enabled the virus to become infectious in humans.

By making the kit free, Arbor Biosciences brings more talent to the table fighting the new coronavirus. Cash-strapped research groups could test ideas within weeks, rather than having to revise a locked-down budget or go through the slow process of applying for a grant.

Jean-Marie Rouillard, an assistant research scientist in chemical engineering at U-M and co-founder and director of technology at Arbor Biosciences, and Alison Devault, director of genomics at Arbor Biosciences, answered questions about the kit and what it could do.

Why is genetic sequencing important for understanding the coronavirus outbreak?

Rouillard: In order to truly understand the evolutionary history of a virus like this one, researchers need to study similar or related viral genome sequences from many different contexts, such as wild animal populations. We anticipate that researchers will use our panel to reconstruct the genetic sequences of the virus SARS-CoV-2formerly known as the 2019 novel coronavirusfrom a variety of human and animal samples.

Many examples of genome sequences are needed to track a diseases historical spread. Already, genetic sequencing has suggested that coronavirus may have been circulating in Washington state since mid-January. In addition, genetic sequencing can help researchers understand how specific parts of the genome are linked to certain disease-causing properties, which may help inform the choice of appropriate medical treatments.

What does your panel do?

Devault: The myBaits Expert kit for the SARS-CoV-2 retrieves and isolates fragments of the viruss genome from any type of sample, such as blood from an infected animal or person. We use known portions of the SARS-CoV-2 sequence to design baits that capture the fragments. Then, a researcher uses specialized software to digitally reconstruct an entire viral genome sequence.

How could it help with outbreaks like COVID-19?

Devault: We expect the research results from using our panel to be more relevant to preventing the next outbreak. The panel is not designed to diagnose, treat or cure a given patient. But it can be used to help determine which animal species are potential sources of COVID-19. In addition to identifying which animals pose a risk now, this use helps the global research community understand when and why this novel pathogenic virus emerged. If we know the conditions that enabled SARS-CoV-2 to appear, we may be able to prevent a future virus from following the same pathway.

How did you start offering these kits for free?

Devault: Several weeks ago, we received a request for such a panel from a researcher, which we were happy to manufacture very quickly and provide to them for free. We felt that due to the overall urgency of understanding the context of this disease, it was clear that we should make comprehensive study kits freely available ASAP to all members of the virology research community that wish to use this tool. While I hope no one would need to write a grant just to afford our kits, funding allocations can create barriers for new applications that dont fit into pre-approved budgets.

Since we announced the panel, weve heard from multiple different virology research groups that would like to use the kit, based in many different countries in North America, Europe and Asia. We were able to scale up production to ensure that we have enough kit materials in stock to quickly respond to all researcher requests.

Arbor Biosciences was started in 2005 by Rouillard and Erdogan Gulari, a professor of chemical engineering at U-M, under the name Biodiscovery LLC. Its technology has enabled some of the most difficult genetic sequencing successes, including the DNA of a horse that lived 700,000 years ago.

Continued here:
Free coronavirus sequencing kits for researchers offered by U-M startup - University of Michigan News

Read More...

Race Is Real, But It’s Not Genetic – SAPIENS

March 18th, 2020 1:47 am

Please note that this article includes an image of human remains.

A friend of mine with Central American, Southern European, and West African ancestry is lactose intolerant. Drinking milk products upsets her stomach, and so she avoids them. About a decade ago, because of her low dairy intake, she feared that she might not be getting enough calcium, so she asked her doctor for a bone density test. He responded that she didnt need one because blacks do not get osteoporosis.

My friend is not alone. The view that black people dont need a bone density test is a longstanding and common myth. A 2006 study in North Carolina found that out of 531 African American and Euro-American women screened for bone mineral density, only 15 percent were African American womendespite the fact that African American women made up almost half of that clinical population. A health fair in Albany, New York, in 2000, turned into a ruckus when black women were refused free osteoporosis screening. The situation hasnt changed much in more recent years.

Meanwhile, FRAX, a widely used calculator that estimates ones risk of osteoporotic fractures, is based on bone density combined with age, sex, and, yes, race. Race, even though it is never defined or demarcated, is baked into the fracture risk algorithms.

Lets break down the problem.

First, presumably based on appearances, doctors placed my friend and others into a socially defined race box called black, which is a tenuous way to classify anyone.

Race is a highly flexible way in which societies lump people into groups based on appearance that is assumed to be indicative of deeper biological or cultural connections. As a cultural category, the definitions and descriptions of races vary. Color lines based on skin tone can shift, which makes sense, but the categories are problematic for making any sort of scientific pronouncements.

Second, these medical professionals assumed that there was a firm genetic basis behind this racial classification, which there isnt.

Third, they assumed that this purported racially defined genetic difference would protect these women from osteoporosis and fractures.

The view that black people dont need a bone density test is a longstanding and common myth.

Some studies suggest that African American womenmeaning women whose ancestry ties back to Africamay indeed reach greater bone density than other women, which could be protective against osteoporosis. But that does not mean being blackthat is, possessing an outward appearance that is socially defined as blackprevents someone from getting osteoporosis or bone fractures. Indeed, this same research also reports that African American women are more likely to die after a hip fracture. The link between osteoporosis risk and certain racial populations may be due to lived differences such as nutrition and activity levels, both of which affect bone density.

But more important: Geographic ancestry is not the same thing as race. African ancestry, for instance, does not tidily map onto being black (or vice versa). In fact, a 2016 study found wide variation in osteoporosis risk among women living in different regions within Africa. Their genetic risks have nothing to do with their socially defined race.

When medical professionals or researchers look for a geneticcorrelateto race, they are falling into a trap: They assume thatgeographic ancestry, which does indeed matter to genetics, can be conflated with race, which does not. Sure, different human populations living in distinct places may statistically have different genetic traitssuch as sickle cell trait (discussed below)but such variation is about local populations (people in a specific region), not race.

Like a fish in water, weve all been engulfed by the smog of thinking that race is biologically real. Thus, it is easy to incorrectly conclude that racial differences in health, wealth, and all manner of other outcomes are the inescapable result of genetic differences.

The reality is that socially defined racial groups in the U.S. and most everywhere else do differ in outcomes. But thats not due to genes. Rather, it is due to systemic differences in lived experience and institutional racism.

Communities of color in the United States, for example, often have reduced access to medical care, well-balanced diets, and healthy environments. They are often treated more harshly in their interactions with law enforcement and the legal system. Studies show that they experience greater social stress, including endemic racism, that adversely affects all aspects of health. For example, babies born to African American women are more than twice as likely to die in their first year than babies born to non-Hispanic Euro-American women.

Systemic racism leads to different health outcomes for various populations. The infant mortality rate, for example, for African American infants is double that for European Americans. Kelly Lacy/Pexels

As a professor of biological anthropology, I teach and advise college undergraduates. While my students are aware of inequalities in the life experiences of different socially delineated racial groups, most of them also think that biological races are real things. Indeed, more than half of Americans still believe that their racial identity is determined by information contained in their DNA.

For the longest time, Europeans thought that the sun revolved around the Earth. Their culturally attuned eyes saw this as obvious and unquestionably true. Just as astronomers now know thats not true, nearly all population geneticists know that dividing people into races neither explains nor describes human genetic variation.

Yet this idea of race-as-genetics will not die. For decades, it has been exposed to the sunlight of facts, but, like a vampire, it continues to suck bloodnot only surviving but causing harm in how it can twist science to support racist ideologies. With apologies for the grisly metaphor, it is time to put a wooden stake through the heart of race-as-genetics. Doing so will make for better science and a fairer society.

In 1619, the first people from Africa arrived in Virginia and became integrated into society. Only after African and European bond laborers unified in various rebellions did colony leaders recognize the need to separate laborers. Race divided indentured Irish and other Europeans from enslaved Africans, and reduced opposition by those of European descent to the intolerable conditions of enslavement. What made race different from other prejudices, including ethnocentrism (the idea that a given culture is superior), is that it claimed that differences were natural, unchanging, and God-given. Eventually, race also received the stamp of science.

Swedish taxonomist Carl Linnaeus divided humanity up into racial categories according to his notion of shared essences among populations, a concept researchers now recognize has no scientific basis. Wikimedia Commons

Over the next decades, Euro-American natural scientists debated the details of race, asking questions such as how often the races were created (once, as stated in the Bible, or many separate times), the number of races, and their defining, essential characteristics. But they did not question whether races were natural things. They reified race, making the idea of race real by unquestioning, constant use.

In the 1700s, Carl Linnaeus, the father of modern taxonomy and someone not without ego, liked to imagine himself as organizing what God created. Linnaeus famously classified our own species into races based on reports from explorers and conquerors.

The race categories he created included Americanus, Africanus, and even Monstrosus (for wild and feral individuals and those with birth defects), and their essential defining traits included a biocultural mlange of color, personality, and modes of governance. Linnaeus described Europeaus as white, sanguine, and governed by law, and Asiaticus as yellow, melancholic, and ruled by opinion. These descriptions highlight just how much ideas of race are formulated by social ideas of the time.

In line with early Christian notions, these racial types were arranged in a hierarchy: a great chain of being, from lower forms to higher forms that are closer to God. Europeans occupied the highest rungs, and other races were below, just above apes and monkeys.

So, the first big problems with the idea of race are that members of a racial group do not share essences, Linnaeus idea of some underlying spirit that unified groups, nor are races hierarchically arranged. A related fundamental flaw is that races were seen to be static and unchanging. There is no allowance for a process of change or what we now call evolution.

There have been lots of efforts since Charles Darwins time to fashion the typological and static concept of race into an evolutionary concept. For example, Carleton Coon, a former president of the American Association of Physical Anthropologists, argued in The Origin of Races (1962) that five races evolved separately and became modern humans at different times.

One nontrivial problem with Coons theory, and all attempts to make race into an evolutionary unit, is that there is no evidence. Rather, all the archaeological and genetic data point to abundant flows of individuals, ideas, and genes across continents, with modern humans evolving at the same time, together.

In this map, darker colors correspond to regions in which people tend to have darker skin pigmentation. Reproduced with permission from Dennis ONeil.

A few pundits such as Charles Murray of the American Enterprise Institute and science writers such as Nicholas Wade, formerly of The New York Times, still argue that even though humans dont come in fixed, color-coded races, dividing us into races still does a decent job of describing human genetic variation. Their position is shockingly wrong. Weve known for almost 50 years that race does not describe human genetic variation.

In 1972, Harvard evolutionary biologist Richard Lewontin had the idea to test how much human genetic variation could be attributed to racial groupings. He famously assembled genetic data from around the globe and calculated how much variation was statistically apportioned within versus among races. Lewontin found that only about 6 percent of genetic variation in humans could be statistically attributed to race categorizations. Lewontin showed that the social category of race explains very little of the genetic diversity among us.

Furthermore, recent studies reveal that the variation between any two individuals is very small, on the order of one single nucleotide polymorphism (SNP), or single letter change in our DNA, per 1,000. That means that racial categorization could, at most, relate to 6 percent of the variation found in 1 in 1,000 SNPs. Put simply, race fails to explain much.

In addition, genetic variation can be greater within groups that societies lump together as one race than it is between races. To understand how that can be true, first imagine six individuals: two each from the continents of Africa, Asia, and Europe. Again, all of these individuals will be remarkably the same: On average, only about 1 out of 1,000 of their DNA letters will be different. A study by Ning Yu and colleagues places the overall difference more precisely at 0.88 per 1,000.

The circles in this diagram represent the relative size and overlap in genetic variation in three human populations. The African population circle (blue) is largest because it contains the most genetic diversity. Genetic diversity in European (orange) and Asian (green) populations is a subset of the variation in Africa. Reproduced by permission of the American Anthropological Association.Adapted from the original, which appeared in the book RACE.Not for sale or further reproduction.

The researchers further found that people in Africa had less in common with one another than they did with people in Asia or Europe. Lets repeat that: On average, two individuals in Africa are more genetically dissimilar from each other than either one of them is from an individual in Europe or Asia.

Homo sapiens evolved in Africa; the groups that migrated out likely did not include all of the genetic variation that built up in Africa. Thats an example of what evolutionary biologists call the founder effect, where migrant populations who settle in a new region have less variation than the population where they came from.

Genetic variation across Europe and Asia, and the Americas and Australia, is essentially a subset of the genetic variation in Africa. If genetic variation were a set of Russian nesting dolls, all of the other continental dolls pretty much fit into the African doll.

What all these data show is that the variation that scientistsfrom Linnaeus to Coon to the contemporary osteoporosis researcherthink is race is actually much better explained by a populations location. Genetic variation is highly correlated to geographic distance. Ultimately, the farther apart groups of people are from one another geographically, and, secondly, the longer they have been apart, can together explain groups genetic distinctions from one another. Compared to race, those factors not only better describe human variation, they invoke evolutionary processes to explain variation.

Those osteoporosis doctors might argue that even though socially defined race poorly describes human variation, it still could be a useful classification tool in medicine and other endeavors. When the rubber of actual practice hits the road, is race a useful way to make approximations about human variation?

When Ive lectured at medical schools, my most commonly asked question concerns sickle cell trait. Writer Sherman Alexie, a member of the Spokane-Coeur dAlene tribes, put the question this way in a 1998 interview: If race is not real, explain sickle cell anemia to me.

In sickle cell anemia, red blood cells take on an unusual crescent shape that makes it harder for the cells to pass through small blood vessels. Mark Garlick/Science Photo Library/AP Images

OK! Sickle cell is a genetic trait: It is the result of an SNP that changes the amino acid sequence of hemoglobin, the protein that carries oxygen in red blood cells. When someone carries two copies of the sickle cell variant, they will have the disease. In the United States, sickle cell disease is most prevalent in people who identify as African American, creating the impression that it is a black disease.

Yet scientists have known about the much more complex geographic distribution of sickle cell mutation since the 1950s. It is almost nonexistent in the Americas, most parts of Europe and Asiaand also in large swaths of Northern and Southern Africa. On the other hand, it is common in West-Central Africa and also parts of the Mediterranean, Arabian Peninsula, and India. Globally, it does not correlate with continents or socially defined races.

In one of the most widely cited papers in anthropology, American biological anthropologist Frank Livingstone helped to explain the evolution of sickle cell. He showed that places with a long history of agriculture and endemic malaria have a high prevalence of sickle cell trait (a single copy of the allele). He put this information together with experimental and clinical studies that showed how sickle cell trait helped people resist malaria, and made a compelling case for sickle cell trait being selected for in those areas. Evolution and geography, not race, explain sickle cell anemia.

What about forensic scientists: Are they good at identifying race? In the U.S., forensic anthropologists are typically employed by law enforcement agencies to help identify skeletons, including inferences about sex, age, height, and race. The methodological gold standards for estimating race are algorithms based on a series of skull measurements, such as widest breadth and facial height. Forensic anthropologists assume these algorithms work.

Skull measurements are a longstanding tool in forensic anthropology. Internet Archive Book Images/Flickr

The origin of the claim that forensic scientists are good at ascertaining race comes from a 1962 study of black, white, and Native American skulls, which claimed an 8090 percent success rate. That forensic scientists are good at telling race from a skull is a standard trope of both the scientific literature and popular portrayals. But my analysis of four later tests showed that the correct classification of Native American skulls from other contexts and locations averaged about two incorrect for every correct identification. The results are no better than a random assignment of race.

Thats because humans are not divisible into biological races. On top of that, human variation does not stand still. Race groups are impossible to define in any stable or universal way. It cannot be done based on biologynot by skin color, bone measurements, or genetics. It cannot be done culturally: Race groupings have changed over time and place throughout history.

Science 101: If you cannot define groups consistently, then you cannot make scientific generalizations about them.

Wherever one looks, race-as-genetics is bad science. Moreover, when society continues to chase genetic explanations, it misses the larger societal causes underlying racial inequalities in health, wealth, and opportunity.

To be clear, what I am saying is that human biogenetic variation is real. Lets just continue to study human genetic variation free of the utterly constraining idea of race. When researchers want to discuss genetic ancestry or biological risks experienced by people in certain locations, they can do so without conflating these human groupings with racial categories. Lets be clear that genetic variation is an amazingly complex result of evolution and mustnt ever be reduced to race.

Similarly, race is real, it just isnt genetic. Its a culturally created phenomenon. We ought to know much more about the process of assigning individuals to a race group, including the category white. And we especially need to know more about the effects of living in a racialized world: for example, how a societys categories Race is real, it just isnt genetic. Its a culturally created phenomenon.and prejudices lead to health inequalities. Lets be clear that race is a purely sociopolitical construction with powerful consequences.

It is hard to convince people of the dangers of thinking race is based on genetic differences. Like climate change, the structure of human genetic variation isnt something we can see and touch, so it is hard to comprehend. And our culturally trained eyes play a trick on us by seeming to see race as obviously real. Race-as-genetics is even more deeply ideologically embedded than humanitys reliance on fossil fuels and consumerism. For these reasons, racial ideas will prove hard to shift, but it is possible.

Over 13,000 scientists have come together to formand publicizea consensus statement about the climate crisis, and that has surely moved public opinion to align with science. Geneticists and anthropologists need to do the same for race-as-genetics. The recent American Association of Physical Anthropologists Statement on Race & Racism is a fantastic start.

In the U.S., slavery ended over 150 years ago and the Civil Rights Law of 1964 passed half a century ago, but the ideology of race-as-genetics remains. It is time to throw race-as-genetics on the scrapheap of ideas that are no longer useful.

We can start by getting my friendand anyone else who has been deniedthat long-overdue bone density test.

Read the original:
Race Is Real, But It's Not Genetic - SAPIENS

Read More...

Patriot Shield Announces Partnership with HempLogic, Launches New Propagation and Distribution Program for 2020 Season – Associated Press

March 18th, 2020 1:47 am

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Click to copy

Denver, Colorado, March 16, 2020 (GLOBE NEWSWIRE) -- Patriot Shield, a leader in hemp logistics and security, is launching a new structured propagation program for hemp farmers for the 2020 growing season. Partnering with HempLogic, a global leader in hemp growing services, Patriot Shield is providing premium seeds from its genetics catalog, placed in potting trays with soil and nutrients, and pre-acclimated to the fields they will grow in.

Patriot Shield is offering this propagation program directly to farmers for as little as $0.50 per unit, cutting out middlemen to reduce upfront costs and enabling farmers to gain more control over their seedlings and clones. Farmers with limited capital can also take advantage of Patriot Shields financing terms, with only half of the investment due upfront and the other half due well after harvest. In addition, farmers can utilize Patriot Shields distribution channels, including its retail and wholesale subsidiary, Veteran HempCo, to further increase their return on investment.

We are very excited to help farmers start the 2020 growing season with superior seeds and service, lower initial costs, great financing, and more options to help sell their crop, said Andrew Ross, CEO of Patriot Shield. Our aim is to allow farmers to focus on what they do best: grow hemp.

In 2019, Patriot Shield transported over 4.5 million hemp seeds, starts, and clones for dozens of established genetics providers and licensed farms. The company has methodically selected and worked with leading global hemp geneticists and consultants to gain deep insights into genetic variables. The companys new structured propagation program for 2020 is a direct reflection of these strategic partnerships.

By advising farmers based on acres available, budget, knowledge, and experience with hemp, Patriot Shield links its catalog of partnered genetics to suit the needs of each individual client.

About Patriot Shield

Founded and managed by U.S. military veterans with deep expertise in logistics and security, Patriot Shield is a leading service provider to all areas of the supply chain in the American cannabis (hemp and marijuana) market, delivering end-to-end hemp logistics solutions from genetics consulting and seedling transport, to harvest strategy and processing, and product warehousing to distribution.

Patriot Shield ensures every link in the hemp supply chain is protected with custom security plans, a veteran guard force, and state-of-the-art technology, like tamper-proofing, GPS tracking, and video monitoring. Starting as a pioneer in the legal interstate transport of hemp in the U.S. through a landmark court case, now has operations or strategic partnerships across the US, including the key markets of California, Colorado, Oklahoma, and Pennsylvania.

# # #

Contact:800-267-8932

Attachment

-- Patriot Shield

Here is the original post:
Patriot Shield Announces Partnership with HempLogic, Launches New Propagation and Distribution Program for 2020 Season - Associated Press

Read More...

Genomics took a long time to fulfil its promise – The Economist

March 18th, 2020 1:47 am

Mar 12th 2020

THE ATOMIC bomb convinced politicians that physics, though not readily comprehensible, was important, and that physicists should be given free rein. In the post-war years, particle accelerators grew from the size of squash courts to the size of cities, particle detectors from the scale of the table top to that of the family home. Many scientists in other disciplines looked askance at the money devoted to this big science and the vast, impersonal collaborations that it brought into being. Some looked on in envy. Some made plans.

The idea that sequencing the whole human genome might provide biology with some big science of its own first began to take root in the 1980s. In 1990 the Human Genome Project was officially launched, quickly growing into a global endeavour. Like other fields of big science it developed what one of the programmes leaders, the late John Sulston, called a tradition of hyperbole. The genome was Everest; it was the Apollo programme; it was the ultimate answer to that Delphic injunction, know thyself. And it was also, in prospect, a cornucopia of new knowledge, new understanding and new therapies.

By the time the completion of a (rather scrappy) draft sequence was announced at the White House in 2000, even the politicians were drinking the Kool-Aid. Tony Blair said it was the greatest breakthrough since antibiotics. Bill Clinton said it would revolutionise the diagnosis, prevention and treatment of most, if not all, human diseases. In coming years, doctors increasingly will be able to cure diseases like Alzheimers, Parkinsons, diabetes and cancer by attacking their genetic roots.

Such hype was always going to be hard to live up to, and for a long time the genome project failed comprehensively, prompting a certain Schadenfreude among those who had wanted biology kept small. The role of genetics in the assessment of peoples medical futures continued to be largely limited to testing for specific defects, such as the BRCA1 and BRCA2 mutations which, in the early 1990s, had been found to be responsible for some of the breast cancers that run in families.

To understand the lengthy gap between the promise and the reality of genomics, it is important to get a sense of what a genome really is. Although sequencing is related to an older technique of genetic analysis called mapping, it produces something much more appropriate to the White House kitchens than to the Map Room: a recipe. The genes strung out along the genomes chromosomesbig molecules of DNA, carefully packedare descriptions of lifes key ingredients: proteins. Between the genes proper are instructions as to how those ingredients should be used.

If every gene came in only one version, then that first human genome would have been a perfect recipe for a person. But genes come in many varietiesjust as chilies, or olive oils, or tinned anchovies do. Some genetic changes which are simple misprints in the ingredients specification are bad in and of themselvesjust as a meal prepared with fuel oil instead of olive oil would be inedible. Others are problematic only in the context of how the whole dish is put together.

The most notorious of the genes with obvious impacts on health were already known before the genome was sequenced. Thus there were already tests for cystic fibrosis and Huntingtons disease. The role of genes in common diseases turned out to be a lot more involved than many had naively assumed. This made genomics harder to turn into useful insight.

Take diabetes. In 2006 Francis Collins, then head of genome research at Americas National Institutes of Health, argued that there were more genes involved in diabetes than people thought. Medicine then recognised three such genes. Dr Collins thought there might be 12. Today the number of genes with known associations to type-2 diabetes stands at 94. Some of these genes have variants that increase a persons risk of the disease, others have variants that lower that risk. Most have roles in various other processes. None, on its own, amounts to a huge amount of risk. Taken together, though, they can be quite predictivewhich is why there is now an over-the-counter genetic test that measures peoples chances of developing the condition.

In the past few years, confidence in sciences ability to detect and quantify such genome-wide patterns of susceptibility has increased to the extent that they are being used as the basis for something known as a polygenic risk score (PRS). These are quite unlike the genetic tests people are used to. Those single-gene tests have a lot of predictive value: a person who has the Huntingtons gene will get Huntingtons; women with a dangerous BRCA1 mutation have an almost-two-in-three chance of breast cancer (unless they opt for a pre-emptive mastectomy). But the damaging variations they reveal are rare. The vast majority of the women who get breast cancer do not have BRCA mutations. Looking for the rare dangerous defects will reveal nothing about the other, subtler but still possibly relevant genetic traits those women do have.

Polygenic risk scores can be applied to everyone. They tell anyone how much more or less likely they are, on average, to develop a genetically linked condition. A recently developed PRS for a specific form of breast cancer looks at 313 different ways that genomes vary; those with the highest scores are four times more likely to develop the cancer than the average. In 2018 researchers developed a PRS for coronary heart disease that could identify about one in 12 people as being at significantly greater risk of a heart attack because of their genes.

Some argue that these scores are now reliable enough to bring into the clinic, something that would make it possible to target screening, smoking cessation, behavioural support and medications. However, hope that knowing their risk scores might drive people towards healthier lifestyles has not, so far, been validated by research; indeed, so far things look disappointing in that respect.

Assigning a PRS does not require sequencing a subjects whole genome. One just needs to look for a set of specific little markers in it, called SNPs. Over 70,000 such markers have now been associated with diseases in one way or another. But if sequencing someones genome is not necessary in order to inspect their SNPs, understanding what the SNPs are saying in the first place requires that a lot of people be sequenced. Turning patterns discovered in the SNPs into the basis of risk scores requires yet more, because you need to see the variations in a wide range of people representative of the genetic diversity of the population as a whole. At the moment people of white European heritage are often over-represented in samples.

The first genome cost, by some estimates, $3bn

The need for masses of genetic information from many, many human genomes is one of the main reasons why genomic medicine has taken off rather slowly. Over the course of the Human Genome Project, and for the years that followed, the cost of sequencing a genome fell quicklyas quickly as the fall in the cost of computing power expressed through Moores law. But it was falling from a great height: the first genome cost, by some estimates, $3bn. The gap between getting cheaper quickly and being cheap enough to sequence lots of genomes looked enormous.

In the late 2000s, though, fundamentally new types of sequencing technology became available and costs dropped suddenly (see chart). As a result, the amount of data that big genome centres could produce grew dramatically. Consider John Sulstons home base, the Wellcome Sanger Institute outside Cambridge, England. It provided more sequence data to the Human Genome Project than any other laboratory; at the time of its 20th anniversary, in 2012, it had produced, all told, almost 1m gigabytesone petabyteof genome data. By 2019, it was producing that same amount every 35 days. Nor is such speed the preserve of big-data factories. It is now possible to produce billions of letters of sequence in an hour or two using a device that could easily be mistaken for a chunky thumb drive, and which plugs into a laptop in the same way. A sequence as long as a human genome is a few hours work.

As a result, thousands, then tens of thousands and then hundreds of thousands of genomes were sequenced in labs around the world. In 2012 David Cameron, the British prime minister, created Genomics England, a firm owned by the government, and tasked initially with sequencing 100,000 genomes and integrating sequencing, analysis and reporting into the National Health Service. By the end of 2018 it had finished the 100,000th genome. It is now aiming to sequence five million. Chinas 100,000 genome effort started in 2017. The following year saw large-scale projects in Australia, America and Turkey. Dubai has said it will sequence all of its three million residents. Regeneron, a pharma firm, is working with Geisinger, a health-care provider, to analyse the genomes of 250,000 American patients. An international syndicate of investors from America, China, Ireland and Singapore is backing a 365m ($405m) project to sequence about 10% of the Irish population in search of disease genes.

Genes are not everything. Controls on their expressionepigentics, in the jargonand the effects of the environment need to be considered, too; the kitchen can have a distinctive effect on the way a recipe turns out. That is why biobanks are being funded by governments in Britain, America, China, Finland, Canada, Austria and Qatar. Their stores of frozen tissue samples, all carefully matched to clinical information about the person they came from, allow study both by sequencing and by other techniques. Researchers are keen to know what factors complicate the lines science draws from genes to clinical events.

Today various companies will sequence a genome commercially for $600-$700. Sequencing firms such as Illumina, Oxford Nanopore and Chinas BGI are competing to bring the cost down to $100. In the meantime, consumer-genomics firms will currently search out potentially interesting SNPs for between $100 and $200. Send off for a home-testing kit from 23andMe, which has been in business since 2006, and you will get a colourful box with friendly letters on the front saying Welcome to You. Spit in a test tube, send it back to the company and you will get inferences as to your ancestry and an assessment of various health traits. The health report will give you information about your predisposition to diabetes, macular degeneration and various other ailments. Other companies offer similar services.

Plenty of doctors and health professionals are understandably sceptical. Beyond the fact that many gene-testing websites are downright scams that offer bogus testing for intelligence, sporting ability or wine preference, the medical profession feels that people are not well equipped to understand the results of such tests, or to deal with their consequences.

An embarrassing example was provided last year by Matt Hancock, Britains health minister. In an effort to highlight the advantages of genetic tests, he revealed that one had shown him to be at heightened risk of prostate cancer, leading him to get checked out by his doctor. The test had not been carried out by Britains world-class clinical genomics services but by a private company; critics argued that Mr Hancock had misinterpreted the results and consequently wasted his doctors time.

23andMe laid off 14% of its staff in January

He would not be the first. In one case, documented in America, third-party analysis of genomic data obtained through a website convinced a woman that her 12-year-old daughter had a rare genetic disease; the girl was subjected to a battery of tests, consultations with seven cardiologists, two gynaecologists and an ophthalmologist and six emergency hospital visits, despite no clinical signs of disease and a negative result from a genetic test done by a doctor.

At present, because of privacy concerns, the fortunes of these direct-to-consumer companies are not looking great. 23andMe laid off 14% of its staff in January; Veritas, which pioneered the cheap sequencing of customers whole genomes, stopped operating in America last year. But as health records become electronic, and health advice becomes more personalised, having validated PRS scores for diabetes or cardiovascular disease could become more useful. The Type 2 diabetes report which 23andMe recently launched looks at over 1,000 SNPs. It uses a PRS based on data from more than 2.5m customers who have opted to contribute to the firms research base.

As yet, there is no compelling reason for most individuals to have their genome sequenced. If genetic insights are required, those which can be gleaned from SNP-based tests are sufficient for most purposes. Eventually, though, the increasing number of useful genetic tests may well make genome sequencing worthwhile. If your sequence is on file, many tests become simple computer searches (though not all: tests looking at the wear and tear the genome suffers over the course of a lifetime, which is important in diseases like cancer, only make sense after the damage is done). If PRSs and similar tests come to be seen as valuable, having a digital copy of your genome at hand to run them on might make sense.

Some wonder whether the right time and place to do this is at birth. In developed countries it is routine to take a pinprick of blood from the heel of a newborn baby and test it for a variety of diseases so that, if necessary, treatment can start quickly. That includes tests for sickle-cell disease, cystic fibrosis, phenylketonuria (a condition in which the body cannot break down phenylalanine, an amino acid). Some hospitals in America have already started offering to sequence a newborns genome.

Sequencing could pick up hundreds, or thousands, of rare genetic conditions. Mark Caulfield, chief scientist at Genomics England, says that one in 260 live births could have a rare condition that would not be spotted now but could be detected with a whole-genome sequence. Some worry, though, that it would also send children and parents out of the hospital with a burden of knowledge they might be better off withoutespecially if they conclude, incorrectly, that genetic risks are fixed and predestined. If there is unavoidable suffering in your childs future do you want to know? Do you want to tell them? If a child has inherited a worrying genetic trait, should you see if you have it yourselfor if your partner has? The ultimate answer to the commandment know thyself may not always be a happy one.

This article appeared in the Technology Quarterly section of the print edition under the headline "Welcome to you"

Go here to read the rest:
Genomics took a long time to fulfil its promise - The Economist

Read More...

Page 650«..1020..649650651652..660670..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick